Latest News
AbbVie Nxera Deal: What Does AbbVie Get for $100 Million Upfront?
The AbbVie Nxera deal gives AbbVie exclusive worldwide rights to develop and commercialise NXE0033744 in inflammatory bowel disease (IBD). The price is $100 million upfront, plus up to $1.37 billion in milestones and tiered royalties. Nxera Pharma announced the...
Latest News
Clinical Trial Results 30 October 2026
Clinical trial results 30 October 2026: head and neck cancer, small cell lung cancer, type 2 diabetes and breast cancer. Genmab’s petosemtamab plus pembrolizumab met both co-primary endpoints in first-line PD-L1-positive head and neck cancer. Amgen’s tarlatamab plus...
Retatrutide vs Ozempic: How Do They Compare in Diabetes?
Retatrutide vs Ozempic now has a head-to-head answer in type 2 diabetes. In an 80-week phase 3 trial, retatrutide lowered A1C by 2.2 percentage points, against 1.8 for Ozempic 2 mg. Body weight fell by 19.5 to 20.9 per cent on retatrutide and 9.4 per cent on Ozempic....
Weight Is Not Composition: What Surgeons See After GLP-1 Weight Loss
The GLP-1 era has given clinicians something they have wanted for decades: medications that produce weight loss approaching what was once possible only with surgery. Semaglutide and tirzepatide routinely deliver reductions of 15% to 20% of body weight in trials, and...
Ferring Gameto Acquisition: What Does Ferring Get From the Deal?
The Ferring Gameto acquisition would give Ferring Pharmaceuticals control of Fertilo, Gameto’s lead investigational fertility programme. Fertilo is derived from induced pluripotent stem cells and is designed to mature eggs outside the body. Ferring and Gameto...
Join The Future Of Life Sciences Media
In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.
Don’t wait for the media to pick up your story. Be the media.
Trending
More News
ALK7 Obesity Drugs: Who Is Developing Them After Roche’s Rona Deal?
Several companies are now developing ALK7 obesity drugs, but human data remain early. On 13 October 2026, Rona Therapeutics licensed an ALK7-targeting RNAi candidate to Roche. Arrowhead, and SiranBio with GSK, have also disclosed ALK7 programmes. Fierce Biotech...
What Pharma Can Learn From Retail as GLP-1 Demand Reshapes Healthcare
Demand for weight-loss medicines in the UK has run well ahead of what the NHS can provide. Researchers at UCL estimate that 1.6 million adults in Great Britain used a medicine to lose weight between early 2024 and early 2025, and that a further 3.3 million were...
Admilparant Approval: What the ALOFT-IPF Result Shows So Far
Admilparant approval for idiopathic pulmonary fibrosis (IPF) is not yet decided, and LSDN found no announced regulatory filing. On 12 October 2026, Bristol Myers Squibb (BMS) reported that its phase 3 ALOFT-IPF trial met its primary endpoint. That was at the 60 mg...
AI Can Accelerate Optimisation, But It Cannot Replace Biological Discovery
Artificial intelligence is increasingly being integrated into the drug discovery process. From the identification of therapeutic targets to the prediction of molecular interactions and ranking of compounds to be developed further, the power of computational tools...
Why Women’s Health Innovation Needs Commercialisation Strategy
Women’s health innovation is experiencing a period of rapid growth. Founders are developing new diagnostics, medical devices, digital platforms, wearables and therapies for conditions that have historically received too little research attention and investment. That...
A Regulatory Playbook for SaMD and Digital Health
Six decisions that shape FDA readiness for software as a medical device and connected digital health products A software team can build a compelling product and still reach the submission stage with a fundamental problem: the evidence supports a narrower claim than...
Beyond Binding: Functional Prediction in GPCR Drug Discovery
In GPCR drug discovery, as elsewhere, teams know the cost of getting early decisions wrong. A corrected JAMA analysis of 63 new drugs and biologics approved by the US Food and Drug Administration between 2009 and 2018 estimated the median capitalised R&D...
An AI Mental Health App Is Not a Therapist: How to Build One Honestly
It's 3am. Thoughts are racing in circles, and there is no one to talk to: friends are asleep, the next appointment with a psychotherapist is weeks away, and not everyone can afford one. So a person either lies awake, scrolls endlessly through social media, or turns to...
Weekly News Roundup | 12 October 2026
Life science news 12 October 2026: three deals, three US approvals and two UK regulatory updates. Shionogi agreed to buy IntraBio for $2bn. Viatris offered $1.65bn for Pacira BioSciences. The FDA approved Tecentriq for Stage III dMMR colon cancer. Shionogi will...
Will the NHS Offer Atezolizumab for dMMR Colon Cancer?
Not yet, and no UK date has been set. The US FDA approved atezolizumab (Tecentriq) on 8 October 2026 for stage III dMMR colon cancer. NICE has an appraisal in scoping, with no publication date. The emc product summary for Tecentriq 1,200 mg lists six indications....
Viatris Pacira Acquisition: What the $1.65bn Deal Buys
The Viatris Pacira acquisition buys two US pain products, Exparel and Zilretta, for $36.50 per share in cash. That values Pacira BioSciences at $1.65 billion. Viatris announced the agreement on 8 October 2026. It expects the deal to close by the end of 2026. Closing...
GLP-1 Therapy: More Than Numbers on a Scale
The advent of GLP-1 medications has radically changed the conversation about the treatment of obesity. Effective treatments such as semaglutide and tirzepatide have grown in popularity and use, with more agents in the pharmaceutical pipeline. However, the treatment of...
ALK7 Obesity Drugs: Who Is Developing Them After Roche’s Rona Deal?
Several companies are now developing ALK7 obesity drugs, but human data remain early. On 13 October 2026, Rona Therapeutics licensed an ALK7-targeting RNAi candidate to Roche. Arrowhead, and SiranBio with GSK, have also disclosed ALK7 programmes. Fierce Biotech...
What Pharma Can Learn From Retail as GLP-1 Demand Reshapes Healthcare
Demand for weight-loss medicines in the UK has run well ahead of what the NHS can provide. Researchers at UCL estimate that 1.6 million adults in Great Britain used a medicine to lose weight between early 2024 and early 2025, and that a further 3.3 million were...
Admilparant Approval: What the ALOFT-IPF Result Shows So Far
Admilparant approval for idiopathic pulmonary fibrosis (IPF) is not yet decided, and LSDN found no announced regulatory filing. On 12 October 2026, Bristol Myers Squibb (BMS) reported that its phase 3 ALOFT-IPF trial met its primary endpoint. That was at the 60 mg...
AI Can Accelerate Optimisation, But It Cannot Replace Biological Discovery
Artificial intelligence is increasingly being integrated into the drug discovery process. From the identification of therapeutic targets to the prediction of molecular interactions and ranking of compounds to be developed further, the power of computational tools...
Why Women’s Health Innovation Needs Commercialisation Strategy
Women’s health innovation is experiencing a period of rapid growth. Founders are developing new diagnostics, medical devices, digital platforms, wearables and therapies for conditions that have historically received too little research attention and investment. That...
A Regulatory Playbook for SaMD and Digital Health
Six decisions that shape FDA readiness for software as a medical device and connected digital health products A software team can build a compelling product and still reach the submission stage with a fundamental problem: the evidence supports a narrower claim than...
Beyond Binding: Functional Prediction in GPCR Drug Discovery
In GPCR drug discovery, as elsewhere, teams know the cost of getting early decisions wrong. A corrected JAMA analysis of 63 new drugs and biologics approved by the US Food and Drug Administration between 2009 and 2018 estimated the median capitalised R&D...
An AI Mental Health App Is Not a Therapist: How to Build One Honestly
It's 3am. Thoughts are racing in circles, and there is no one to talk to: friends are asleep, the next appointment with a psychotherapist is weeks away, and not everyone can afford one. So a person either lies awake, scrolls endlessly through social media, or turns to...
Weekly News Roundup | 12 October 2026
Life science news 12 October 2026: three deals, three US approvals and two UK regulatory updates. Shionogi agreed to buy IntraBio for $2bn. Viatris offered $1.65bn for Pacira BioSciences. The FDA approved Tecentriq for Stage III dMMR colon cancer. Shionogi will...
Will the NHS Offer Atezolizumab for dMMR Colon Cancer?
Not yet, and no UK date has been set. The US FDA approved atezolizumab (Tecentriq) on 8 October 2026 for stage III dMMR colon cancer. NICE has an appraisal in scoping, with no publication date. The emc product summary for Tecentriq 1,200 mg lists six indications....
Viatris Pacira Acquisition: What the $1.65bn Deal Buys
The Viatris Pacira acquisition buys two US pain products, Exparel and Zilretta, for $36.50 per share in cash. That values Pacira BioSciences at $1.65 billion. Viatris announced the agreement on 8 October 2026. It expects the deal to close by the end of 2026. Closing...
GLP-1 Therapy: More Than Numbers on a Scale
The advent of GLP-1 medications has radically changed the conversation about the treatment of obesity. Effective treatments such as semaglutide and tirzepatide have grown in popularity and use, with more agents in the pharmaceutical pipeline. However, the treatment of...
Featured Articles
Further News
Clinical Trial Results | 9 October 2026
The clinical trial results 9 October 2026 span haematological oncology, rare skeletal disease, metabolic medicine, coeliac disease and autoimmunity. The FDA expanded Eli Lilly’s Jaypirca into previously untreated chronic lymphocytic leukaemia. BridgeBio Pharma’s oral...
Food and Medicines: Why the Leaflet and the Label Do Not Match
Why closing the gap between clinical nutrition advice and the food labels in the supermarket aisle is a data problem before it is an education problem. Around 11 million deaths in 2017 were attributable to dietary risk factors, according to the Global Burden of...
Petrelintide in Type 2 Diabetes: How Does It Compare?
Petrelintide in type 2 diabetes cannot yet be ranked against tirzepatide or semaglutide, because the trial designs differ. Zealand Pharma, which develops the drug with Roche, reported Phase 2b ZUPREME-2 topline data on 7 October 2026. Mean weight loss reached up to...
More Data, Smarter AI: Is Life Sciences Making Better Decisions?
The life sciences sector has always depended on the quality of evidence behind its decisions. Today, the volume of evidence, and the speed at which it can be analysed, is changing dramatically with artificial intelligence. In September, the National Commission into...
Newly Diagnosed Glioblastoma Trial Misses Primary Survival Endpoint
MimiVax and Roswell Park Comprehensive Cancer Center reported topline Phase 2b data on 7 October 2026. The SURVIVE trial tested the survivin peptide vaccine SurVaxM in newly diagnosed glioblastoma. The primary endpoint was overall survival. The full study population...
Digital Twins Need a New Validation Trigger: Drift, Not Deployment
A digital twin commissioned to mirror a manufacturing process is, by design, built to keep learning. It ingests live sensor data, recalibrates its internal parameters, and narrows the gap between what it predicts and what the physical process is actually doing. That's...
Pharmacogenomics Has Left the Lab. Now Comes the Hard Part.
In every industry, there is a lag period between breakthrough and implementation, but perhaps none so long as in healthcare, where medical advances such as pharmacogenomics (PGx) might not show up in practices for years or even decades. While there are myriad reasons...
Traditional Botanical Knowledge: A Research Lead, Not a Health Claim
I like to call myself a conduit between ancient healing wisdom and modern life. I came to the US thirty years ago to be trained as a pathologist, but I grew up among generations of herbalists. My family roots and my research background have shaped how I view the...
Digital Validation in Life Sciences: CSA, Annex 11 and Annex 22 in 2026
For most of the past three decades, validating a computerised system in a GMP facility has usually meant paper. Teams compiled binders of test scripts, wet-ink signatures and printed screenshots. That model is now under pressure, and digital validation in life...
The Future of Diagnostics Is Molecularly Precise
The landscape of modern healthcare is increasingly reliant on the speed, accuracy, and accessibility of In Vitro Diagnostics (IVD). From rapid point-of-care infectious disease tests to complex oncology biomarker profiling, IVD assays play a central role in clinical...
EGFR Exon 20 Insertion Trial Misses Its Primary Endpoint
ArriVent BioPharma has reported a miss on the primary endpoint of its pivotal Phase 3 trial. The study enrolled patients with EGFR exon 20 insertion lung cancer. The global FURVENT study tested the oral inhibitor firmonertinib against platinum chemotherapy. All...
Healthcare AI Needs Trusted Evidence and Communication Standards
The resignation of Anthropic researcher Jacob Coxon has brought renewed attention to the risks of increasingly powerful artificial intelligence. According to the Associated Press, Coxon warned that competitive pressure was overtaking safety considerations at leading...
Further News
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.
Don’t wait for the media to pick up your story. Be the media.
See More Articles
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.